Innovations • Global Impact • In The News • Our People

AAHI Around the World

AAHI leadership shares programmatic updates, provides expert opinion in vaccine innovation and development, and engages with international industry experts on how to efficiently advance health solutions that are accessible to the people who most need them.


The latest scientific breakthroughs at AAHI.

Vaccine Adjuvants for Global Health

Dr. Christopher Fox, Senior Vice President of formulations at AAHI, co-chaired and presented at the Vaccine Adjuvants for Global Health webinar at the biennial Global Vaccine and Immunization Research Forum (GVIRF) hosted by the National Institute of Allergy and Infectious Diseases, the Bill & Melinda Gates Foundation, and the World Health Organization. Vaccine development experts discussed the global demand for vaccine adjuvants, approaches to adjuvant and formulation selection for vaccine R&D, and currently available adjuvants for vaccine developers. Watch the webinar today!

Make your products accessible to those who need them most. Collaborate with AAHI.



Collaboration across communities.

Explore AAHI's different areas of impact.

Houston, Texas

AAHI Participates in New ARPANET-H Health Innovation Network

We are thrilled to be part of ARPA-H's new network established to create efficiencies in solving the nation's health problems. ARPANET-H is composed of three regional hubs that are supported by a nationwide network. AAHI is a member of the Customer Experience hub, working with other entities across private and public sectors to bring accessible and affordable vaccines and therapies to all.

Help us make impossible vaccines possible.


By Anna Maria Barry-Jester


Tuberculosis (TB) is one of the leading infectious disease threats in the world, claiming 1.5 million lives annually, a number that is rising for the first time in over a decade. The need for a TB vaccine that works for adults is increasingly urgent. Five years ago, an adjuvanted TB vaccine candidate, M72F that contains GSK's As01 adjuvant formulation, was shown to prevent infection in over half of clinical trial participants, but the M72F vaccine is not publicly available.

Why doesn't the world have access to this TB vaccine for adults?

The short answer: supply of an essential and scarce raw material is being allocated to GSK's priorities - its blockbuster vaccines Shringrix (shingles) and Arexvy (RSV). The AS01 adjuvant used in the M72F vaccine is derived from oil in the bark of a rare Chilean Soapbark tree. This oil is in short supply, and despite the urgent demand for a TB vaccine, more profitable vaccines take commercial precedence.


Collaboration across communities.

Explore our different areas of impact.

Featured Post

October 24-28 | Merida, Yucatan

AAHI scientists presented results of a preclinical study evaluating AAHI's nasal spray amebiasis vaccine candidate in non-human primates at XX International Seminar on Amebiasis, the premier conference bringing together leading experts working to prevent and treat amebiasis - a parasite transmitted by exposure to infested human feces that burdens areas of the world with poor sanitation.

A Day In The Life of AAHI Employees

This month, we introduce you to Michael Davis, PhD, a Senior Scientist on AAHI's RNA Vaccine Team, led by Dr. Emily Voigt. Michael is responsible for managing the Research Associates on the team and supports activities under AAHI's recent NIH award to develop a temperature stable chikungunya RNA vaccine candidate through Phase 1 clinical trials.

Learn more about Michael's everyday working at AAHI today!

Openings and Opportunities


The Director of Research Administration will be responsible for managing pre-award and post-award activities for AAHI's sponsored research awards, working across the organization to provide support developing, submitting, and tracking new funding opportunities.


The Research Associate will be responsible for supporting vaccine studies in rodent models of viral disease, running standard immunoassays on animal serum and cell samples and handling BSL2 viral samples under appropriate safety conditions.


The Research Associate will be responsible for aiding the development of new vaccines against emerging and re-emerging viral disease, supporting preclinical vaccine studies in rodent models of infectious disease.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.